Key Highlights

  • Revenue for the third quarter ended September 30, 2026 rose 35% to USD 18.95 million from USD 14.0 million, with product Revenue of USD 15.8 million and service and contract revenue of USD 3.2 million.
  • The loss from continuing operations narrowed to USD 4.6 million, or USD 0.11 a share, from USD 14.9 million, or USD 0.41, as a prior-year USD 10.7 million contingent consideration charge did not recur.
  • Management said it now expects 2026 revenue of USD 68.5 million to USD 70 million, raising the low end, and said it shipped more than 300 devices, a record, lifting the installed base to about 4,400.
  • Cash, cash equivalents and marketable securities were USD 99.1 million with no debt, and management said adjusted EBITDA was a loss of USD 1.7 million in the quarter.

Record Shipments Lift Revenue 35% to USD 18.95 Million

908 Devices (NASDAQ:MASS) filed its Quarterly Report and held its call on November 10, 2026. The company makes handheld devices that identify unknown chemicals, including mass spectrometry and infrared products used by first responders, military and law enforcement customers. Revenue was USD 18.95 million, against USD 14.0 million a year earlier, and management said the prior-year figure included USD 1.2 million from NIRLab. Gross Profit was USD 10.0 million, a 53% Margin that management described as consistent with last year. Infrared products made up 55% of revenue in the quarter, and management said international customers were 40% of revenue, double the prior year.

Guidance Floor Moves Up While Losses Narrow

Management said the company now expects full-year 2026 revenue of USD 68.5 million to USD 70 million, representing growth of 22% to 25%, and left out revenue from the AVCAD chemical detector program because it may move to a commercial product. It said the adjusted gross margin should be in the mid to high 50% range and adjusted EBITDA loss in the mid-single-digit millions, roughly a third lower than 2025. Operating expenses were USD 15.5 million against USD 23.7 million, mainly because of a USD 11 million non-cash swing in contingent consideration. Selling, general and administrative expense rose USD 2.8 million to USD 12.0 million on NIRLab costs and other items.

Mix, Recurring Revenue Share and the Next-Generation MX908

Recurring revenue was USD 5.1 million, or 27% of revenue, as device placements outpaced service growth. Adjusted gross margin was 58%, down 40 basis points, which management attributed to lower-margin international product sales. Management said it sold about 100 NIRLab devices and shipped about two thirds of a USD 6 million order from an Asia Pacific correction agency. It is targeting early access shipments of a smaller, lighter next-generation MX908 by year end, which it expects to drive growth in 2027. Cash use in the quarter was USD 2.4 million, and the filing says Liquidity covers at least the next 12 months, an estimate that may prove wrong. The filing notes that government order timing can make revenue uneven, since large orders are concentrated in a few customers.

Where Things Stand

Management raised the floor because third-quarter revenue grew 35% and shipments set a record, not because profitability turned. 908 Devices (NASDAQ:MASS) still lost USD 4.6 million, with an adjusted EBITDA loss of USD 1.7 million, and recurring revenue slipped to 27% of the total. Only the low end of guidance was raised, and the material gives no prior range or share price reaction. Watch fourth-quarter device orders, any AVCAD commercial purchase, the next-generation MX908 shipments and progress toward adjusted EBITDA breakeven.